Capvizr
News · All summaries
Healthcare & Life Sciences
CORE Biomedicine
Series A$21 million
RoundSeries A
Amount$21 million
LeadUTokyo Innovation Platform Co
HQCambridge, United States
DateJuly 28, 2026
THE DEAL, AT A GLANCE

CORE Biomedicine

From the announcement
Who is involvedBacked by UTokyo Innovation Platform Co, InnoPinnacle Fund, Mitsubishi UFJ Capital CoFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
What happenedCORE Biomedicine raised $21M Series A, announced 2026-07-28From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Why it mattersCORE Biomedicine's $21 Million Series A financing and AMED grant award support development of precision oncology medicines that go beyond genomics.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

CORE Biomedicine · Financing Record

Explore source-linked visual explanations for CORE Biomedicine. Unsupported claims are withheld while source review continues.

Record 9130 · Recorded date: 2026-07-28

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime